A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib
Titel:
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib
Auteur:
Camidge, D. Ross Moran, Teresa Demedts, Ingel Grosch, Heidrun Mileham, Kathryn Molina, Julian Juan-Vidal, Oscar Bepler, Gerold Goldman, Jonathan W Park, Keunchil Wallin, Johan Wijayawardana, Sameera R Wang, Xuejing Aimee Wacheck, Volker Smit, Egbert